This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

December 14-16, 2020|★ VIRTUAL EVENT, Delivered in Eastern Standard Time (EST)

THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS

Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders

View Demo of Virtual Platform


It is more important than ever for the Antibody Engineering & Therapeutics community to connect with one another, strategize and share ideas — All in a safe, responsible way.

Through our fully interactive and sophisticated virtual platform, you will be able to take advantage of this extended time to engage with people who matter to your business, be inspired by thought leaders who are making an impact and evolve together as we emerge from this crisis.

To see how a virtual conference will operate, watch our short demo for more information.
(The video demo is of another Informa Connect event, but the experience will be the same) 

NEW EXCITING CONTENT FOR 2020!

  • Inducible Activation of Antibodies to Enhance Therapeutic Index NEW!!!
  • Novel Insights into Immunoglobulin Structures (i.e. Fabs, Fc, Antibody Oligomers and Complexes) NEW!!!
  • Responding to the COVID-19 Pandemic with Antibodies, Small Molecule Drugs and Vaccines NEW!!!
  • Sourcing Disease-specific Human Antibodies from Patient Repertoires NEW!!!
  • Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and Beyond NEW!!!
  • FcR and Antibody Effector Functions NEW!!!
  • Antibody Affinity Maturation and Developability Improvement for Lead Optimization NEW!!!

The Most Innovative Science
The Most Innovative Science
  • Access Keynote presentations from trail-blazing researchers.
  • Hear the about the latest research with over 135 case studies and industry updates.
  • View over 100 scientific posters for collaboration opportunities
  • Evaluate technologies at the scientific briefings to help accelerate your R&D
Partner with Global Antibody Innovators and Suppliers
Partner with Global Antibody Innovators and Suppliers
  • Collaborate with 1,000+ from leading pharma, biotech, and academia from around the globe.
  • Connect with 75+ leading technology and service providers.
  • Schedule meetings or chat with potential partners

2020 CONFERENCE SESSION TOPICS


Antibody Selection and Screening in Early Discovery
Antibody Selection and Screening in Early Discovery

Session Chair:

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Novel Non-cancer Targets for Therapeutic Antibodies
Novel Non-cancer Targets for Therapeutic Antibodies

Session Chair:

James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

Transforming Therapeutic Targets
Transforming Therapeutic Targets

Session Chairs:

Janine Schuurman, Ph.D., Vice President, Research, Genmab, The Netherlands

James A. Ernst, Ph.D., Senior Director, Head of Development Sciences, Xencor


Developments in ADC Technology
Developments in ADC Technology

Session Chair:

Sally Ward, Ph.D., Professor, University of Southampton and Texas A&M University Health Science Center 

Inducible Activation of Antibodies to Enhance Therapeutic Index
Inducible Activation of Antibodies to Enhance Therapeutic Index

Session Chair:

Paul J. Carter, Ph.D., Senior Director and Senior Staff Scientist, Antibody Engineering, Genentech, Inc.

Bispecific T cell Engagers
Bispecific T cell Engagers

Session Chairs:

Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and EVP and Head of R&D, Lava Therapeutics, The Netherlands

Katherine Harris, Ph.D., Senior Director of Discovery at Teneobio


Novel Insights into Immunoglobulin Structures (i.e. Fabs, Fc, Antibody Oligomers and Complexes)
Novel Insights into Immunoglobulin Structures (i.e. Fabs, Fc, Antibody Oligomers and Complexes)

Session Chair:

Andrew Ward, Ph.D., Professor, Department of Integrative Structural and Computational Biology, The Scripps Research Institute

Responding to the COVID-19 Pandemic with Antibodies, Small Molecule Drugs and Vaccines
Responding to the COVID-19 Pandemic with Antibodies, Small Molecule Drugs and Vaccines

Session Chair:

Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbiology, The Scripps Research Institute

Expressing Antibodies by Gene Therapy and/or Viral Therapies
Expressing Antibodies by Gene Therapy and/or Viral Therapies

Session Chair:

Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland


Sourcing Disease-specific Human Antibodies from Patient Repertoires
Sourcing Disease-specific Human Antibodies from Patient Repertoires

Session Chairs:

Jennifer Cochran, Ph.D., Professor and Department Chair of Bioengineering, Stanford University

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom

Computational Modeling of Antibody-Antigen Interactions
Computational Modeling of Antibody-Antigen Interactions

Session Chairs:

Jamie K. Scott, M.D., Ph.D., Professor Emeritus, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada

Jean-Philippe Bürckert, Ph.D., Director of Computational Immunology, Distributed Bio

Juan Carlos Almagro, Ph.D., Founder and Director, GlobalBio

Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and Beyond
Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and Beyond

Session Chairs:

Anne Messer, Ph.D., Professor of Biomedical Sciences, University at Albany and Principal Investigator, Neural Stem Cell Institute, Regenerative Research Foundation

Gregory Adams, Ph.D., Chief Scientific Officer, Elucida Oncology

Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI


FcR and Antibody Effector Functions
FcR and Antibody Effector Functions

Session Chair:

Falk Nimmerjahn, Ph.D., Professor, Division of Genetics, University of Erlangen-Nuremberg, Germany

Immune Oncology Antibodies
Immune Oncology Antibodies

Session Chair:

K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Workshop: Antibody Affinity Maturation and Developability Improvement for Lead Optimization
Workshop: Antibody Affinity Maturation and Developability Improvement for Lead Optimization

Session Chair:

Stephen Parmley, Ph.D., Vice President, Molecular Biology & Protein Sciences, AnaptysBio


Workshop: Engineering Chimeric Antigen Receptors, T cell Receptors and Cytokines
Workshop: Engineering Chimeric Antigen Receptors, T cell Receptors and Cytokines

Session Chair:

Sai Reddy, Ph.D., Associate Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland

Get Global Recognition of Your Work by Presenting a Poster

Present a Scientific Poster in Poster Viewing Hall 

Highlight your organization’s latest research by presenting a scientific poster in your own dedicated virtual room, which will be accessible to all attendees throughout the event. As a virtual poster presenter, you can:

  • Post a PDF of your poster for attendees to download
  • Host a pre-recorded audio or video introduction of your poster
  • Discuss your poster in real-time during our dedicated poster viewing times
  • Hold face-to-face virtual meetings with attendees who visit your poster room

Get the latest news.
As it happens

Sign up to get the latest on the agenda and speakers.

About the Antibody Society

The Antibody Society is an international, non-profit representing individuals and organizations involved in antibody-related research and development. The Society has a variety of initiatives and working groups focused on improving the antibody field. 

We are:

- Creating opportunities for education and networking;

- Monitoring and reporting advances in the commercial pipeline for antibody and CAR-T therapeutics;

- Creating standards for characterizing antibody and T-cell receptor repertoires, and engaging this field;

- Engaging government and international agencies on matters concerning the antibody community;

 Please join us!

CONNECT WITH KEY BUYERS AT Antibody Engineering & Therapeutics

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.  

Contact Kristin Skahan: KSkahan@informaconnectls.com | +1-857-504-6730